Exploring ADMET properties and the anticancer potential mechanism of a new organoselenium compound using network pharmacology and in vitro study
DOI:
https://doi.org/10.5902/2179460X88474Keywords:
Pharmacokinetic properties, Cell culture, TargetsAbstract
Complex genetic mutations and malignant transformations in cancers have plagued the world. Modified variants of nucleoside analogs have proven to be allies in the hope of promising new treatments in anticancer therapy. However, it sometimes faces difficulties related to its low bioavailability and resistance mechanisms. In this study, investigative and initial in silico and in vitro analyses were performed on a new organoselenium compound, 5-Se-(phenyl)-3-(ferulic-amido)-thymidine (AFAT-Se). Different in silico platforms were used to explore the ADMET properties and possible pharmacological and toxicological effects of AFAT-Se, and its anticancer potential was assessed by in vitro studies. AFAT-Se complied with Lipinski's rules, exhibiting favorable pharmacokinetic properties, interaction with common drug metabolic enzymes, toxicities that require further study, and cytotoxicity toward the HT-29 tumor cell line, as evidence of its potential as an antineoplastic agent. Therefore, critical molecular targets were identified in cancer-related pathways; thus, the organoselenium AFAT-Se is a promising candidate for further studies on this pathology.
Downloads
References
Ahmed, S., Alam, W., Aschner, M., Alsharif, K. F., Albrakati, A., Saso, L., & Khan, H. (2022). Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomedicine & Pharmacotherapy, 155, 113797. DOI: https://doi.org/10.1016/j.biopha.2022.113797
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Pliss, G. B., Bespalov, V. G., Alexandrov, V. A., Stukov, A. N., Anikin, I. V., Alimova, I. N., Egormin, P. A., Panchenko, A. V., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., & Yurova, M. N. (2012). Rodent models for the preclinical evaluation of drugs suitable for pharmacological intervention in aging. Expert Opinion on Drug Discovery, 7(1), 85-95. DOI: https://doi.org/10.1517/17460441.2012.642361
Aouidate, A., Ghaleb, A., Ghamali, M., Ousaa, A., Sbai, A., Bouachrine, M., & Lakhlifi, T. (2018). 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase. Computational Biology and Chemistry, 74, 201-211. DOI: https://doi.org/10.1016/j.compbiolchem.2018.03.008
Ayed, K., Nabi, L., Akrout, R., Mrizak, H., Gorrab, A., Bacha, D., Boussen, H., & Gati, A. (2023). Obesity and cancer: Focus on leptin. Molecular biology reports, 50(7), 6177-6189. DOI: https://doi.org/10.1007/s11033-023-08525-y
Cao, N., Li, X., Zhang, W., Wang, Q., Liang, Y., Zhou, F., & Xiao, X. (2022). Research progress of signaling pathways of the natural substances intervene dyslipidemia. Experimental and Therapeutic Medicine, 24(2), 494. DOI: https://doi.org/10.3892/etm.2022.11421
Chagas, C. M., Moss, S., & Alisaraie, L. (2018). Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski’s Rule of Five. International journal of pharmaceutics, 549(1-2), 133-149. DOI: https://doi.org/10.1016/j.ijpharm.2018.07.046
Constantinescu, T., Lungu, C. N., & Lung, I. (2019). Lipophilicity as a central component of drug-like properties of chalchones and flavonoid derivatives. Molecules, 24(8), 1505. DOI: https://doi.org/10.3390/molecules24081505
Cui, M., Wang, H., Yao, X., Zhang, D., Xie, Y., Cui, R., & Zhang, X. (2019). Circulating microRNAs in cancer: potential and challenge. Frontiers in genetics, 10, 626. DOI: https://doi.org/10.3389/fgene.2019.00626
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014). Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chemistry & biology, 21(9), 1115-1142. DOI: https://doi.org/10.1016/j.chembiol.2014.08.013
Druzhilovskiy, D. S., Rudik, A. V., Filimonov, D. A., Gloriozova, T. A., Lagunin, A. A., Dmitriev, A. V., Pogodin, P. V., Dubovskaya, V. I., Ivanov, S. M., Tarasova, O. A., Bezhentsev, V. M., Murtazalieva, K. A., Semin, M. I., Maiorov, I. S., Gaur, A. S., Sastry, G. N. & Poroikov, V. V. (2017). Computational platform Way2Drug: from the prediction of biological activity to drug repurposing. Russian Chemical Bulletin, 66, 1832-1841. DOI: https://doi.org/10.1007/s11172-017-1954-x
Esteves, F., Rueff, J., & Kranendonk, M. (2021). The central role of cytochrome P450 in xenobiotic metabolism—a brief review on a fascinating enzyme family. Journal of xenobiotics, 11(3), 94-114. DOI: https://doi.org/10.3390/jox11030007
Fatima, S., Gupta, P., Sharma, S., Sharma, A., & Agarwal, S. M. (2020). ADMET profiling of geographically diverse phytochemical using chemoinformatic tools. Future medicinal chemistry, 12(1), 69-87. DOI: https://doi.org/10.4155/fmc-2019-0206
Fong, C. W. (2015). Permeability of the blood–brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. The Journal of membrane biology, 248(4), 651-669. DOI: https://doi.org/10.1007/s00232-015-9778-9
Gandin, V.; Khalkar, P.; Braude, J.; Fernandes, A. P. (2018). Organic Selenium Compounds as Potential Chemotherapeutic Agents for Improved Cancer Treatment. Free Radical Biology and Medicine, 127, 80–97. DOI: https://doi.org/10.1016/j.freeradbiomed.2018.05.001
García-Miranda, A., Garcia-Hernandez, A., Castañeda-Saucedo, E., Navarro-Tito, N., & Maycotte, P. (2022). Adipokines as regulators of autophagy in obesity-linked cancer. Cells, 11(20), 3230. DOI: https://doi.org/10.3390/cells11203230
Garrido, A., Lepailleur, A., Mignani, S. M., Dallemagne, P., & Rochais, C. (2020). hERG toxicity assessment: Useful guidelines for drug design. European journal of medicinal chemistry, 195, 112290. DOI: https://doi.org/10.1016/j.ejmech.2020.112290
George, B., Wen, X., Jaimes, E. A., Joy, M. S., & Aleksunes, L. M. (2021). In vitro inhibition of renal OCT2 and MATE1 secretion by antiemetic drugs. International journal of molecular sciences, 22(12), 6439. DOI: https://doi.org/10.3390/ijms22126439
Gomes, L. L., Araújo, A. P. de. Neto., Medeiros, F. L. S. de, Santana, M. T. P., Santos, T. A. dos, Oliveira, H. M. B. F. de., Guênes, G. M. T., Alves, M. A. S. G., Penha, E. S. da., Anjos, R. M. dos., Oliveira, V. F. de., Sousa, A. P. de., & Oliveira, A. A. de. F° (2020). Análise in silico da toxicidade do monoterpeno eucaliptol. Research, Society and Development, 9(5), e158953092-e158953092. DOI: https://doi.org/10.33448/rsd-v9i5.3092
Guan, M., Guo, L., Ma, H., Wu, H., & Fan, X. (2021). Network pharmacology and molecular docking suggest the mechanism for biological activity of rosmarinic acid. Evidence‐Based Complementary and Alternative Medicine, 2021(1), 5190808. DOI: https://doi.org/10.1155/2021/5190808
Guinan, M., Benckendorff, C., Smith, M., & Miller, G. J. (2020). Recent advances in the chemical synthesis and evaluation of anticancer nucleoside analogues. Molecules, 25(9), 2050. DOI: https://doi.org/10.3390/molecules25092050
He, S., Moutaoufik, M. T., Islam, S., Persad, A., Wu, A., Aly, K. A., Fonge, H., Mohan, B., & Cayabyab, F. S. (2020). HERG channel and cancer: a mechanistic review of carcinogenic processes and therapeutic potential. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1873(2), 188355. DOI: https://doi.org/10.1016/j.bbcan.2020.188355
Hu, B., Zhou, X., Mohutsky, M. A., & Desai, P. V. (2020). Structure–property relationships and machine learning models for addressing CYP3A4-mediated victim drug–drug interaction risk in drug discovery. Molecular Pharmaceutics, 17(9), 3600-3608. DOI: https://doi.org/10.1021/acs.molpharmaceut.0c00637
Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L., & Lerman, L. O. (2022). Cellular senescence: the good, the bad and the unknown. Nature Reviews Nephrology, 18(10), 611-627. DOI: https://doi.org/10.1038/s41581-022-00601-z
Ivanović, V., Rančić, M., Arsić, B., & Pavlović, A. (2020). Lipinski’s rule of five, famous extensions and famous exceptions. Chem Naissensis, 3(1), 171-177. DOI: https://doi.org/10.46793/ChemN3.1.171I
Kokic, G., Chernev, A., Tegunov, D., Dienemann, C., Urlaub, H., & Cramer, P. (2019). Structural basis of TFIIH activation for nucleotide excision repair. Nature communications, 10(1), 2885. DOI: https://doi.org/10.1038/s41467-019-10745-5
Kondža, M., Bojić, M., Tomić, I., Maleš, Ž., Rezić, V., & Ćavar, I. (2021). Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules, 26(10), 3018. DOI: https://doi.org/10.3390/molecules26103018
Korzekwa, K., & Nagar, S. (2017). Drug distribution part 2. Predicting volume of distribution from plasma protein binding and membrane partitioning. Pharmaceutical research, 34, 544-551 DOI: https://doi.org/10.1007/s11095-016-2086-y
Lagunin, A. A., Rudik, A. V., Pogodin, P. V., Savosina, P. I., Tarasova, O. A., Dmitriev, A. V., Ivanov, S. M., Biziukova, N. Y., Druzhilovskiy, D. S., Filimonov, D. A., & Poroikov, V. V. (2023). CLC-Pred 2.0: a freely available web application for in silico prediction of human cell line cytotoxicity and molecular mechanisms of action for druglike compounds. International Journal of Molecular Sciences, 24(2), 1689. DOI: https://doi.org/10.3390/ijms24021689
Leal, J. G., Piccoli, B. C., Oliveira, C. S., da Silva, F. D. A., Omage, F. B., da Rocha, J. B. T., ... & Rodrigues, O. E. (2022). Synthesis, antioxidant and antitumoral activity of new 5′-arylchalcogenyl-3′-N-(E)-feruloyl-3′, 5′-dideoxy-amino-thymidine (AFAT) derivatives. New Journal of Chemistry, 46(46), 22306-22313. DOI: https://doi.org/10.1039/D2NJ03487E
Lee, M. van der, Guchelaar, H. J., & Swen, J. J. (2021). Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics, 22(16), 1081-1089. DOI: https://doi.org/10.2217/pgs-2021-0093
Leopoldo, M., Nardulli, P., Contino, M., Leonetti, F., Luurtsema, G., & Colabufo, N. A. (2019). An updated patent review on P-glycoprotein inhibitors (2011-2018). Expert opinion on therapeutic patents, 29(6), 455-461. DOI: https://doi.org/10.1080/13543776.2019.1618273
Li G-M., Pearlman, A. H., & Hsieh, P. (2013). DNA mismatch repair and the DNA damage response. Encyclopedia of Biological Chemistry, 38, 94-101. DOI: https://doi.org/10.1016/j.dnarep.2015.11.019
Lipinski, C. A. (2004). Lead-and drug-like compounds: the rule-of-five revolution. Drug discovery today: Technologies, 1(4), 337-341. DOI: https://doi.org/10.1016/j.ddtec.2004.11.007
Liu, L., Michowski, W., Kolodziejczyk, A., & Sicinski, P. (2019). The cell cycle in stem cell proliferation, pluripotency and differentiation. Nature cell biology, 21(9), 1060-1067. DOI: https://doi.org/10.1038/s41556-019-0384-4
Macedo, L. B., Nogueira-Librelotto, D. R., Mathes, D., Vargas, J. M. de., Rosa, R. M. da., Rodrigues, O. E. D., Vinardell, M. P., Monstserrat, M., & Rolim, C. M. B. (2021). Overcoming MDR by Associating Doxorubicin and pH-Sensitive PLGA Nanoparticles Containing a Novel Organoselenium Compound—An In Vitro Study. Pharmaceutics, 14(1), 80. DOI: https://doi.org/10.3390/pharmaceutics14010080
Mathes, D., Macedo, L. B., Pieta, T. B., Maia, B. C., Rodrigues, O. E. D., Leal, J. G., Wendt, M., Rolim, C. M. B., Mitjans, M., & Nogueira-Librelotto, D. R. (2024). Co-Delivery of an Innovative Organoselenium Compound and Paclitaxel by pH-Responsive PCL Nanoparticles to Synergistically Overcome Multidrug Resistance in Cancer. Pharmaceutics, 16(5), 590. DOI: https://doi.org/10.3390/pharmaceutics16050590
Matthews, H. K., Bertoli, C., & Bruin, R. A. de. (2022). Cell cycle control in cancer. Nature reviews Molecular cell biology, 23(1), 74-88. DOI: https://doi.org/10.1038/s41580-021-00404-3
Mudaliar, P., Nalawade, A., Devarajan, S., & Aich, J. (2022). Therapeutic potential of autophagy activators and inhibitors in lung and breast cancer-a review. Molecular Biology Reports, 49(11), 10783-10795. DOI: https://doi.org/10.1007/s11033-022-07711-8
Niraj, J., Färkkilä, A., & D'Andrea, A. D. (2019). The Fanconi anemia pathway in cancer. Annual review of cancer biology, 3(1), 457-478. DOI: https://doi.org/10.1146/annurev-cancerbio-030617-050422
Odi, R., Bibi, D., Wager, T., & Bialer, M. (2020). A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond. Epilepsia, 61(8), 1543-1552. DOI: https://doi.org/10.1111/epi.16597
Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of medicinal chemistry, 58(9), 4066-4072. DOI: https://doi.org/10.1021/acs.jmedchem.5b00104
Pires, D. E., Kaminskas, L. M., & Ascher, D. B. (2018). Prediction and optimization of pharmacokinetic and toxicity properties of the ligand. Computational drug discovery and design, 271-284. DOI: https://doi.org/10.1007/978-1-4939-7756-7_14
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC endocrine disorders, 22(1), 63. DOI: https://doi.org/10.1186/s12902-022-00980-1
Raies, A. B., & Bajic, V. B. (2016). In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdisciplinary Reviews: Computational Molecular Science, 6(2), 147-172. DOI: https://doi.org/10.1002/wcms.1240
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H. (2019). Drug-induced liver injury: highlights of the recent literature. Drug safety, 42, 365-387. DOI: https://doi.org/10.1007/s40264-018-0743-2
Rowland, M., Roberts, M. S., & Pang, K. S. (2022). In defense of current concepts and applications of clearance in drug development and therapeutics. Drug Metabolism and Disposition, 50(2), 187-190. DOI: https://doi.org/10.1124/dmd.121.000637
Sak, M., Al-Fayz, Y. S., Elsawy, H., & Shaaban, S. (2022). Novel Organoselenium Redox Modulators with Potential Anticancer, Antimicrobial, and Antioxidant Activities. Journal of Organoselenium Research, 11(7), 1931. DOI: https://doi.org/10.3390/antiox11071231
Shields, M. (2017). Chemotherapeutics. In Badal, S. & Delgoda, R., (Eds.). Pharmacognosy: Fundamentals, Applications and Strategies (pp. 295-313). Academic Press. DOI: https://doi.org/10.1016/B978-0-12-802104-0.00014-7
Shultz, M. D. (2018). Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective. Journal of Medicinal Chemistry, 62(4), 1701-1714. DOI: https://doi.org/10.1021/acs.jmedchem.8b00686
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: a cancer journal for clinicians, 73(1), 17-48. DOI: https://doi.org/10.3322/caac.21763
Steinbrueck, A., Sedgwick, A. C., Brewster, J. T., Yan, K. C., Shang, Y., Knoll, D. M., Vargas-Zúñiga, G. I., He, X.-P., Tian, H. & Sessler, J. L. (2020). Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents. Chemical Society Reviews, 49(12), 3726-3747. DOI: https://doi.org/10.1039/C9CS00373H
Sun, Y., McCorvie, T. J., Yates, L. A., & Zhang, X. (2020). Structural basis of homologous recombination. Cellular and Molecular Life Sciences, 77(1), 3-18. DOI: https://doi.org/10.1007/s00018-019-03365-1
Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S. Bork, P., Jensen, L. J., & Mering, C. von. (2023). The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic acids research, 51(D1), D638-D646. DOI: https://doi.org/10.1093/nar/gkac1000
Taneja, G., Chu, C., Maturu, P., Moorthy, B., & Ghose, R. (2018). Role of c-Jun-N-terminal kinase in pregnane X receptor-mediated induction of human cytochrome P4503A4 in vitro. Drug Metabolism and Disposition, 46(4), 397-404. DOI: https://doi.org/10.1124/dmd.117.079160
Ubhi, T., & Brown, G. W. (2019). Exploiting DNA replication stress for cancer treatment. Cancer research, 79(8), 1730-1739. DOI: https://doi.org/10.1158/0008-5472.CAN-18-3631
Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 45(12), 2615-2623. DOI: https://doi.org/10.1021/jm020017n
Yu, X. (2020). Prediction of chemical toxicity to Tetrahymena pyriformis with four-descriptor models. Ecotoxicology and Environmental Safety, 190, 110146. DOI: https://doi.org/10.1016/j.ecoenv.2019.110146
Wanat, K. (2020). Biological barriers, and the influence of protein binding on the passage of drugs across them. Molecular biology reports, 47(4), 3221-3231. DOI: https://doi.org/10.1007/s11033-020-05361-2
Wang, Y., & Chen, X. (2020). A joint optimization QSAR model of fathead minnow acute toxicity based on a radial basis function neural network and its consensus modeling. RSC advances, 10(36), 21292-21308. DOI: https://doi.org/10.1039/D0RA02701D
Williams, A. B., & Schumacher, B. (2016). p53 in the DNA-damage-repair process. Cold Spring Harbor perspectives in medicine, 6(5), a026070. DOI: https://doi.org/10.1101/cshperspect.a026070
Wright, W. C., Chenge, J., & Chen, T. (2019). Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. Liver research, 3(3-4), 132-142. DOI: https://doi.org/10.1016/j.livres.2019.08.001
Zadorozhnii, P. V., Kiselev, V. V., & Kharchenko, A. V. (2022). In silico ADME profiling of salubrinal and its analogues. Future Pharmacology, 2(2), 160-197. DOI: https://doi.org/10.3390/futurepharmacol2020013
Zeiger, E. (2019). The test that changed the world: The Ames test and the regulation of chemicals. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 841, 43-48. DOI: https://doi.org/10.1016/j.mrgentox.2019.05.007
Published
Issue
Section
License
Copyright (c) 2025 Ciência e Natura
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
To access the DECLARATION AND TRANSFER OF COPYRIGHT AUTHOR’S DECLARATION AND COPYRIGHT LICENSE click here.
Ethical Guidelines for Journal Publication
The Ciência e Natura journal is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.
In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review Articles should also be objective, comprehensive, and accurate accounts of the state of the art. The Authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding Author should ensure that there is a full consensus of all Co-authors in approving the final version of the paper and its submission for publication.
Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An Editor must not use unpublished information in the editor's own research without the express written consent of the Author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.
Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that Authors can use them for improving the paper. Any selected Reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the Editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
